Abstract: Disclosed are methods and apparatus for delivering an active pharmaceutical ingredient (API) to a substrate, such as an edible. In particular, an API-containing liquid is dosed from a dosing head in small increments. Because the volume of API-containing liquid dosed in each increment is known, and the concentration of API in the API-containing liquid is known, the amount of API incrementally driven out of the dosing head in the API-containing liquid is known. Among the API driven out of the dosing head, a majority can be delivered to the substrate, for instance as individual successive droplets or as a stream. A minority can remain adhered to the dosing head as a residual API. A wash fluid can be applied to the dosing head to remove the residual API and deliver the residual API to the substrate.

Abstract: A layered edible product includes a core and at least one active layer that is supported by the core. The at least one active layer can include a respective API. The edible product is configured to be placed against a mucosal surface of the oral cavity, which causes the respective API of the at least one active layer to enter the bloodstream through the mucosal surface. The core can be ingested gastrointestinally or can be dissolvable against the mucosal surface or both. The core can include a core API, or optionally the core can be API-free.

Abstract: Disclosed are methods and apparatus for delivering an active pharmaceutical ingredient (API) to a substrate, such as an edible. In particular, an API-containing liquid is dosed from a dosing head in small increments. Because the volume of API-containing liquid dosed in each increment is known, and the concentration of API in the API-containing liquid is known, the amount of API incrementally driven out of the dosing head in the API-containing liquid is known. Among the API driven out of the dosing head, a majority can be delivered to the substrate, for instance as individual successive droplets or as a stream. A minority can remain adhered to the dosing head as a residual API. A wash fluid can be applied to the dosing head to remove the residual API and deliver the residual API to the substrate.

Abstract: Systems and methods can apply machine learning techniques to predict biological responses. One of the methods is performed by at least one processor executing executable logic including at least one machine learning model trained to predict biological responses. The method includes receiving first sequence data of a first molecular sequence, receiving second sequence data of a second molecular sequence, and predicting a biological response for the second molecular sequence based at least partly on the received first and second sequence data.

Abstract: This present disclosure provides reliable methods and apparatus for delivering microdroplets containing an active pharmaceutical ingredient (API) to underlying substrates. A control system is provided to ensure that the API dosage is both accurate and repeatable.

Abstract: The present disclosure provides compositions comprising at least two messenger RNAs (mRNAs) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and/or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen, and methods of eliciting an immune response by administering said compositions.

Abstract: Disclosed herein are hybrid multivalent vaccine or immunogenic compositions comprising (i) one or more influenza virus proteins selected from one or more influenza virus hemagglutinin (HA) proteins, one or more influenza virus neuraminidase (NA) proteins, or a combination thereof; and (ii) one or more ribonucleic acid molecules encoding one or more influenza virus proteins selected from one or more influenza virus HA proteins, one or more influenza virus NA proteins, or a combination thereof. Also disclosed are methods of using the vaccine or immunogenic compositions.

Abstract: Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

Abstract: Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

Abstract: This present disclosure provides reliable methods and apparatus for delivering a pharmaceutical active ingredient to an edible substrate. In some examples, the pharmaceutical active ingredient is delivered to voids that are formed in the edible substrate. The voids can then be closed as desired. The edible substrate can be configured as a food product or a dosage form as desired.

Abstract: Aspects and embodiments of the present invention include an apparatus, including a body suit, for providing improved interactions with media content, particularly interactive digital content. The body suit is rotatable around a base and includes one or more of knee, hip and elbow joints that can be driven by motors, or manually. Furthermore, one or more of the knee, hip and elbow can apply resistance to motion by way of braking means. The motors and braking means of aspects and embodiments of the invention, as well as force feedback attachments, provide a sense of realism through improved interaction with interactive digital content. In addition, real world movements of the body suit can be interpreted into digital interactions within an interactive digital content environment.

Abstract: A layered edible product includes a core and at least one active layer that is supported by the core. The at least one active layer can include a respective API. The edible product is configured to be placed against a mucosal surface of the oral cavity, which causes the respective API of the at least one active layer to enter the bloodstream through the mucosal surface. The core can be ingested gastrointestinally or can be dissolvable against the mucosal surface or both. The core can include a core API, or optionally the core can be API-free.

Abstract: Methods and apparatus are described for delivering API to a smokable structures and tea bags that contain a fill material. The fill material can include cannabis plant matter, such as cannabis flowers. In one example, an injection tube can be inserted into a smokable structure, and the API can be emitted as a spray. Other methods examples of delivering API to smokable structures are disclosed.

Abstract: This present disclosure provides reliable methods and apparatus for delivering microdroplets containing an active pharmaceutical ingredient (API) to underlying substrates. A control system is provided to ensure that the API dosage is both accurate and repeatable.

Abstract: This present disclosure provides reliable methods and apparatus for delivering a pharmaceutical active ingredient to a food product that is produced in a batch process. In one example, the active pharmaceutical ingredient is added after the batch food product has been cooked and cooled. The food product can be a candy, a baked good, or any alternative food product that is mixed as a batch and subsequently cooked and cooled.

Abstract: In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.

Abstract: Systems and methods can apply machine learning techniques to predict biological responses. One of the methods is performed by at least one processor executing executable logic including at least one machine learning model trained to predict biological responses. The method includes receiving first sequence data of a first molecular sequence, receiving second sequence data of a second molecular sequence, and predicting a biological response for the second molecular sequence based at least partly on the received first and second sequence data.

Abstract: This present disclosure provides reliable methods and apparatus for delivering a pharmaceutical active ingredient to a substrate. In some examples, the pharmaceutical active ingredient is applied to the substrate after the substrate has been fully prepared. The substrate can be an edible product or an inedible substrate. The edible product can be a baked or otherwise cooked good. In some examples, the edible product can be fruits and/or nuts. The method and apparatus for delivering the pharmaceutical agent can be configured to deliver microquantities of the pharmaceutical active ingredient to the substrate.

Abstract: A structure including a barrier is described. In embodiments, a micro-electronic component may have a first face and a second face, wherein the second face includes interconnect structures and is opposite the first face. A fill material, such as a capillary underfill material (CUF), may fill a gap between the micro-electronic component and the substrate and substantially surround the interconnect structures. In embodiments, a barrier structure may be located on the surface of the substrate and along a perimeter or outside perimeter of the micro-electronic component, wherein a height of the barrier structure exceeds a height of the fill material in at least a portion of an open region of the substrate to confine the fill material to an area bordered by the barrier structure.

Abstract: In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.